Tolcapone is under clinical development by Corino Therapeutics and currently in Phase II for Familial Amyloid Cardiomyopathy. According to GlobalData, Phase II drugs for Familial Amyloid Cardiomyopathy have an 89% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Tolcapone’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Tolcapone (CRX-1008) is under development for the prevention and treatment of transthyretin amyloidosis (ATTR), ATTR-cardiomyopathy (familial amyloid cardiomyopathy), hATTR-Polyneuropathy (hereditary/familial amyloid neuropathies), and hATTR-Leptomeningeal. The drug candidate is administered orally and is a repurposed drug. The drug candidate targets transthyretin. It is developed based on the in silico ligand-based virtual screening repositioning technology.
Corino Therapeutics overview
Corino Therapeutics ( Corino) is a biopharmaceutical company focused on acquiring, developing, and commercializing innovative products for the treatment of a variety of human diseases, particularly orphan indications. Corino is headquartered in the US.
For a complete picture of Tolcapone’s drug-specific PTSR and LoA scores, buy the report here.